AR109528A1 - Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih - Google Patents
Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vihInfo
- Publication number
- AR109528A1 AR109528A1 ARP170102536A ARP170102536A AR109528A1 AR 109528 A1 AR109528 A1 AR 109528A1 AR P170102536 A ARP170102536 A AR P170102536A AR P170102536 A ARP170102536 A AR P170102536A AR 109528 A1 AR109528 A1 AR 109528A1
- Authority
- AR
- Argentina
- Prior art keywords
- hiv
- envelope proteins
- trimmers
- hiv envelope
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
Abstract
Proteínas de la envoltura del virus de inmunodeficiencia humana (VIH) con mutaciones que estabilizan la forma trimérica de la proteína de la envoltura. Las proteínas de la envoltura del VIH tienen algunas sustituciones de aminoácidos en posiciones específicas en la secuencia de la proteína de la envoltura. Las proteínas de la envoltura del VIH que se describen en la presente tienen un porcentaje mejorado de la formación de trímeros y/o un rendimiento de trímeros mejorado en comparación con una proteína de la envoltura del VIH que no tiene una o más de las sustituciones de aminoácidos indicadas. También se proveen moléculas de ácido nucleico y vectores que codifican las proteínas de la envoltura del VIH, así como composiciones que contienen las proteínas de la envoltura del VIH, los ácidos nucleicos y los vectores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16188866 | 2016-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109528A1 true AR109528A1 (es) | 2018-12-19 |
Family
ID=57017955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102536A AR109528A1 (es) | 2016-09-15 | 2017-09-14 | Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih |
Country Status (30)
Country | Link |
---|---|
US (3) | US10793607B2 (es) |
EP (2) | EP3512543B1 (es) |
JP (2) | JP7178344B2 (es) |
KR (1) | KR102513146B1 (es) |
CN (1) | CN109689091A (es) |
AR (1) | AR109528A1 (es) |
AU (2) | AU2017327672B2 (es) |
BR (1) | BR112019004593A2 (es) |
CA (1) | CA3036959A1 (es) |
CY (1) | CY1124518T1 (es) |
DK (1) | DK3512543T3 (es) |
EA (1) | EA201990715A1 (es) |
ES (1) | ES2824525T3 (es) |
HR (1) | HRP20201458T1 (es) |
HU (1) | HUE052008T2 (es) |
IL (2) | IL294832A (es) |
LT (1) | LT3512543T (es) |
MA (1) | MA46230B1 (es) |
MD (1) | MD3512543T2 (es) |
MX (1) | MX2019002938A (es) |
MY (1) | MY190534A (es) |
PH (1) | PH12019500280A1 (es) |
PL (1) | PL3512543T3 (es) |
PT (1) | PT3512543T (es) |
RS (1) | RS60919B1 (es) |
SG (2) | SG10202001956UA (es) |
SI (1) | SI3512543T1 (es) |
TW (1) | TWI742158B (es) |
WO (1) | WO2018050747A1 (es) |
ZA (1) | ZA201901597B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016369326B2 (en) | 2015-12-15 | 2019-02-21 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
CA3016352A1 (en) | 2016-03-03 | 2017-09-08 | Duke University | Compositions and methods for inducing hiv-1 antibodies |
AU2017259275C1 (en) * | 2016-05-02 | 2022-01-27 | The Scripps Research Institute | Compositions and methods related to HIV-1 immunogens |
US10273268B2 (en) | 2016-06-16 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
HUE052008T2 (hu) | 2016-09-15 | 2021-04-28 | Janssen Vaccines & Prevention Bv | Trimert stabilizáló HIV-burokfehérje-mutációk |
EP3519428A4 (en) | 2016-10-03 | 2020-07-08 | Duke University | METHOD FOR IDENTIFYING IMMUNOGENIC BY TARGETING UNLIKIBLE MUTATIONS |
MA49397A (fr) | 2017-06-15 | 2020-04-22 | Bavarian Nordic As | Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation |
BR112020000867A2 (pt) * | 2017-07-19 | 2020-07-21 | Janssen Vaccines & Prevention B.V. | mutações da proteína do envelope do hiv estabilizando o trímero |
CA3103460A1 (en) | 2018-06-13 | 2019-12-19 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
EA038287B1 (ru) * | 2018-06-18 | 2021-08-04 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизирующие тример мутации белка оболочки hiv |
WO2020072169A1 (en) * | 2018-10-01 | 2020-04-09 | Duke University | Hiv-1 envelope stabilizing mutations |
AU2020211990A1 (en) * | 2019-01-22 | 2021-08-12 | 2Seventy Bio, Inc. | Methods and systems for manufacturing viral vectors |
CN110184298B (zh) * | 2019-05-15 | 2023-05-16 | 武汉璟泓科技股份有限公司 | Hiv突变型表面糖蛋白及其纳米化抗原与制备方法 |
US20220401546A1 (en) * | 2019-11-14 | 2022-12-22 | Emory University | HIV Immunogens, Vaccines, and Methods Related Thereto |
EP4245767A1 (en) * | 2020-11-12 | 2023-09-20 | Xiamen University | Modified membrane protein of human immunodeficiency virus and use thereof |
US20220265813A1 (en) | 2021-02-23 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Trimer Stabilizing HIV Envelope Protein Mutation |
WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
WO2023192835A1 (en) * | 2022-03-27 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Base-covered hiv-1 envelope ectodomains and their use |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
EP1214333A4 (en) | 1999-09-17 | 2005-01-19 | Dana Farber Cancer Inst Inc | STABILIZED SOLUBLE GLYCOPROTEINTRIMERE |
NZ524661A (en) | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
CA2466413C (en) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
CA2477954C (en) | 2002-04-25 | 2012-07-10 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
WO2004050856A2 (en) | 2002-12-03 | 2004-06-17 | University Of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
EP2359851A3 (en) | 2003-03-28 | 2011-08-31 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
CA2539021A1 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
EP2371387A3 (en) * | 2003-09-17 | 2012-01-25 | Duke University | HIV consensus sequence antigens and their use in vaccina |
US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
US20080274134A1 (en) | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
JP4772045B2 (ja) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Cmv/r核酸コンストラクトを含むaidsに対するワクチン |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
CN1857345B (zh) * | 2005-05-08 | 2010-09-01 | 谢秀琼 | 一种治疗偏头痛的药物组合物及其制备方法 |
WO2007005934A2 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
EP1917040A4 (en) | 2005-08-23 | 2012-12-12 | Univ California | POLYVALENT VACCINE |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
EP2040747A4 (en) | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | SOLUBLE STABILIZED TRIMERIC HIV ENV PROTEINS AND USES THEREOF |
CA2667358A1 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
EP2137210B1 (en) | 2007-03-02 | 2016-10-19 | GlaxoSmithKline Biologicals SA | Novel method and compositions |
LT3335728T (lt) | 2008-10-10 | 2020-03-10 | Children`S Medical Center Corporation | Biocheminiu požiūriu stabilizuota živ-1 env trimero vakcina |
WO2010059732A1 (en) | 2008-11-18 | 2010-05-27 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
CN105399833B (zh) | 2010-01-04 | 2019-09-06 | Kj 生物科学有限公司 | 用于疫苗和诊断学的Dps融合蛋白 |
AU2011209175B2 (en) | 2010-01-28 | 2016-02-04 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
EP3556396B1 (en) | 2010-08-31 | 2022-04-20 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF |
US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
CA3200425A1 (en) | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
SG11201505229XA (en) | 2013-01-07 | 2015-08-28 | Beth Israel Hospital | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
US10400015B2 (en) * | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
RS61902B1 (sr) | 2014-09-26 | 2021-06-30 | Beth Israel Deaconess Medical Ct Inc | Metodi i kompozicije za indukovanje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
US20180052173A1 (en) | 2015-03-18 | 2018-02-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
AU2016369326B2 (en) | 2015-12-15 | 2019-02-21 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
US10273268B2 (en) | 2016-06-16 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
HUE052008T2 (hu) * | 2016-09-15 | 2021-04-28 | Janssen Vaccines & Prevention Bv | Trimert stabilizáló HIV-burokfehérje-mutációk |
BR112020000867A2 (pt) * | 2017-07-19 | 2020-07-21 | Janssen Vaccines & Prevention B.V. | mutações da proteína do envelope do hiv estabilizando o trímero |
-
2017
- 2017-09-14 HU HUE17769027A patent/HUE052008T2/hu unknown
- 2017-09-14 MX MX2019002938A patent/MX2019002938A/es unknown
- 2017-09-14 EP EP17769027.8A patent/EP3512543B1/en active Active
- 2017-09-14 EA EA201990715A patent/EA201990715A1/ru unknown
- 2017-09-14 PL PL17769027T patent/PL3512543T3/pl unknown
- 2017-09-14 IL IL294832A patent/IL294832A/en unknown
- 2017-09-14 RS RS20201208A patent/RS60919B1/sr unknown
- 2017-09-14 AR ARP170102536A patent/AR109528A1/es unknown
- 2017-09-14 CA CA3036959A patent/CA3036959A1/en active Pending
- 2017-09-14 JP JP2019514316A patent/JP7178344B2/ja active Active
- 2017-09-14 SI SI201730416T patent/SI3512543T1/sl unknown
- 2017-09-14 DK DK17769027.8T patent/DK3512543T3/da active
- 2017-09-14 US US15/704,651 patent/US10793607B2/en active Active
- 2017-09-14 CN CN201780054555.6A patent/CN109689091A/zh active Pending
- 2017-09-14 ES ES17769027T patent/ES2824525T3/es active Active
- 2017-09-14 BR BR112019004593A patent/BR112019004593A2/pt unknown
- 2017-09-14 PT PT177690278T patent/PT3512543T/pt unknown
- 2017-09-14 IL IL265186A patent/IL265186B/en unknown
- 2017-09-14 EP EP20179463.3A patent/EP3747463A1/en active Pending
- 2017-09-14 MD MDE20190798T patent/MD3512543T2/ro unknown
- 2017-09-14 AU AU2017327672A patent/AU2017327672B2/en active Active
- 2017-09-14 SG SG10202001956UA patent/SG10202001956UA/en unknown
- 2017-09-14 LT LTEP17769027.8T patent/LT3512543T/lt unknown
- 2017-09-14 KR KR1020197007592A patent/KR102513146B1/ko active IP Right Grant
- 2017-09-14 MY MYPI2019001242A patent/MY190534A/en unknown
- 2017-09-14 WO PCT/EP2017/073141 patent/WO2018050747A1/en active Search and Examination
- 2017-09-14 MA MA46230A patent/MA46230B1/fr unknown
- 2017-09-14 SG SG11201901206SA patent/SG11201901206SA/en unknown
- 2017-09-15 TW TW106131855A patent/TWI742158B/zh active
-
2019
- 2019-02-08 PH PH12019500280A patent/PH12019500280A1/en unknown
- 2019-03-14 ZA ZA2019/01597A patent/ZA201901597B/en unknown
-
2020
- 2020-08-13 US US16/947,694 patent/US11365222B2/en active Active
- 2020-09-14 HR HRP20201458TT patent/HRP20201458T1/hr unknown
- 2020-10-09 CY CY20201100952T patent/CY1124518T1/el unknown
- 2020-11-13 AU AU2020267278A patent/AU2020267278B2/en not_active Expired - Fee Related
-
2022
- 2022-06-08 US US17/805,873 patent/US11820796B2/en active Active
- 2022-11-14 JP JP2022181566A patent/JP2023011941A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109528A1 (es) | Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih | |
EA201792045A1 (ru) | Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr | |
CO2019000395A2 (es) | Genes de mini–distrofina optimizados y casetes de expresión y su uso | |
EA202090919A1 (ru) | Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a | |
WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
CY1124682T1 (el) | Ανταγωνιστες toy trpv4 | |
EA201891415A1 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
BR112017017867A2 (pt) | métodos e composições para tratamento de doenças oculares genéticas | |
EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
EA201491470A1 (ru) | Композиции фактора viii и способы получения и использования подобных | |
EA201791841A1 (ru) | Новые белки, специфичные к пиовердину и пиохелину | |
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
EA201991798A1 (ru) | Стабильные при хранении составы | |
EA201491277A1 (ru) | Противораковый слитый белок | |
EA201591643A1 (ru) | Варианты пертузумаба и их аналитическая характеристика | |
CY1123403T1 (el) | Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων | |
EA201501028A1 (ru) | Конструкции митохондриальных белков и их применение | |
CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
EA201691589A1 (ru) | Стабилизированные основанные на фибронектине каркасные молекулы | |
PH12020500025A1 (en) | Trimer stabilizing hiv envelope protein mutations |